Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells
Fig 3
Combined treatment of IVM and 4-OHT further reduced cell viability and ERα and HER2 levels in ER⁺ and endocrine-resistant breast cancer cell lines.
IC25 values of IVM and/or 4-OHT-treated concentrations were obtained from MTT assays. Cell viability was evaluated in three MCF-7 breast cancer cell lines: (A) MCF-7, (B) MCF-7/LCC2, and (C) MCF-7/LCC9 at 24 h. The graphs showed the mean ± SEM at each treated concentration. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with nontreatment control by one-way ANOVA (n = 3). (D) Western blots were performed in three MCF-7 breast cancer cell lines after the treatments with concentrations at IC25 values of IVM and/or 4-OHT for 24 h. The fold change on the protein level of ERα was assessed in (E) MCF-7, (F) MCF-7/LCC2, and (G) MCF-7/LCC9 cells and HER2 in (H) MCF-7, (I) MCF-7/LCC2, and (J) MCF-7/LCC9 cells. The graphs displayed the mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001, comparing between two groups (n = 3).